AGÑÇÓ鼯ÍŹٷ½ÍøÕ¾

ÄúÏÖÔÚµÄλÖãº ÍøÕ¾Ê×Ò³>´ÙÏúÖÐÐÄ

Neuron | Õü¾ÈÐÇÐÇÖ®×Ó£¡ÉϿƴó¹Ü¼ªËÉ×é½ÒʾASH1Lµ¥±¶²»×ãÖÂСÊó×Ô±ÕÖ¢µÄÉñ¾­»úÖÆ

2022-03-03

ÖÐÊàÉñ¾­ÏµÍ³µÄ·¢ÓýºÍѧϰÓÕµ¼µÄÉñ¾­»·Â·Öع¹¶¼Êܵ½»ùÒò±í´ïµÄʱ¿Õµ÷¿Ø¡£×éµ°°×ÖØ¹¹ÔÚÉúÀíºÍ²¡ÀíÌõ¼þϵ÷¿ØÕâÀà»ùÒòµÄ±í´ïÆð×ÅÖØÒª×÷Óã¬Òò´Ë£¬×éµ°°×ÖØ¹¹¿ÉÄܳÉΪÐí¶àÖØ´óÄÔ¼²²¡µÄDZÔÚÒ©Îï°Ðµã¡£
×éµ°°×¼×»ù×ªÒÆÃ¸±»È·ÈÏΪÐí¶àÉñ¾­·¢ÓýÕϰ­µÄ·çÏÕ»ùÒò¡£Ash1lÊÇÒ»ÖÖ×éµ°°×¼×»ù×ªÒÆÃ¸£¬ÊôÓÚÈýÐØ¼Ò×壨trxG£©µ°°×µÄ³ÉÔ±Ö®Ò»£¬ÆäÄÜÞ׿¹¶àÊáµ°°×¼Ò×å¶Ô»ùÒòת¼µÄÒÖÖÆ¹¦ÄÜ¡£Ä¿Ç°Ô½À´Ô½¶àµÄÑо¿Ö¤Ã÷£¬Ash1l»ùÒò¹¦ÄÜȱʧÊÇ×Ô±ÕÖ¢Æ×ϵÕϰ­£¨autism spectrum disorder, ASD£©·¢ÉúµÄÊ×ҪΣÏÕÒòËØ£¬È»¶ø£¬¹ØÓÚAsh1lµ¥±¶Ìå²»×ãµ¼ÖÂÓë ASDÏà¹ØÖ²¡»úÖÆÉв»Çå³þ¡£

2022Äê1ÔÂ26ÈÕ£¬ÉϺ£¿Æ¼¼´óѧÉúÃü¿ÆÑ§Óë¼¼ÊõѧԺ¹Ü¼ªËɽÌÊÚÍŶÓÀûÓÃAsh1lȱʧСÊóÄ£ÐÍ¡¢ÐÐΪѧ·¶Ê½¡¢¹âÒÅ´«Ñ§µÈ¶à¸ö¼¼ÊõÊֶη¢ÏÖAsh1lµ¥±¶Ìå²»×ãµ¼ÖÂСÊóASDÑùÐÐΪ£¬ÆÆ»µ»î¶¯ÒÀÀµµÄÍ»´¥ÐÞ¼ô¹ý³Ì£¬²¢¶Ô¸ÃÏÖÏó½øÐÐÁËϵͳÐÔ̽Ë÷£¬Ïà¹ØÑо¿³É¹û¿¯·¢ÔÚÉñ¾­¿ÆÑ§ÆÚ¿¯NeuronÉÏ£¬±êÌâΪASH1L haploinsufficiency results in autistic-like phenotypes in mice and links Eph receptor gene to autism spectrum disorder

½á¹û
ǰÄÔÉñ¾­ÔªAsh1lµ¥±¶Ìå²»×ãµ¼ÖÂСÊóµÄASDÑù±íÐÍ

Ê×ÏÈ£¬×÷Õ߱ȽÏÁËAsh1l+/-СÊó[1,2]ºÍWTСÊóµÄÐÐΪѧ±íÐÍ£¬ÔÚAsh1l+/-СÊóÖмì²âµ½Á˵¥±¶Ìå²»×㣬ͬʱ£¬¿õ³¡ÊµÑ飨the open-field test£©ºÍÂñÖéʵÑ飨the marble-burying test£©ÐÐΪѧ·¶Ê½½á¹ûÏÔʾ£¬Ash1l+/-СÊó±íÏÖÀàËÆ½¹ÂÇ¡¢Öظ´¿Ì°åµÄÐÐΪ£¨Í¼1A,B£©¡£´ËÍ⣬¶Ô³öÉúºó7-9Ì죨P7-P9£©Ð¡Êó½øÐÐÓ×Êó³¬Éù·¢Éù²âÊÔ£¬·¢ÏÖAsh1l+/-СÊóÔÚÉúÃüÔçÆÚ´æÔÚÏÖ¹µÍ¨Õϰ­µÄÏÖÏó£¨Í¼1C£©¡£ÈýÏäÉ罻ʵÑ飨three-chamber assay£©½á¹ûÏÔʾAsh1l+/-СÊóÒ²±íÏÖ³öÉç½»Õϰ­£¨Í¼1D£©¡£ÕâЩ½á¹ûÌáʾÁËAsh1lÍ»±äСÊó±íÏÖ³öµäÐ͵Ä×Ô±ÕÖ¢ÑùÐÐΪ£¬°üÀ¨¹µÍ¨À§ÄÑ£¬Öظ´¿Ì°åÐÐΪ¡¢Éç½»Õϰ­µÈ¡£

µ¥Ï¸°û»ùÒò±í´ï·ÖÎö·¢ÏÖ£¬ÔÚÖÐÊàÉñ¾­ÏµÍ³ÖУ¬ Ash1lÓÅÏÈÔÚÉñ¾­ÔªÖбí´ï£¨Í¼1E£©¡£Òò´Ë£¬Ñо¿ÈËÔ±½èÖúԭλÔÓ½»Á´Ê½·´Ó¦£¨HCR-FISH£©×ö½øÒ»²½ÑéÖ¤£¬·¢ÏÖÔÚÆ¤²ãÉñ¾­ÔªÖУ¬Ash1lÑôÐÔÐźÅÓëMap2ÑôÐÔÐźţ¨(Map2+£¬Éñ¾­Ôª±êÖ¾Î¸ß¶ÈÖØµþ£¨Í¼1F£© £»ÔÚMap2-ϸ°ûÖУ¬Ash1lÐźŵãÊýÁ¿Ã÷ÏÔ¼õÉÙ¡£ÕâÌáʾÁËÉñ¾­ÔªÖÐAsh1l¹¦ÄÜȱʧ¿ÉÄܵ¼ÖÂ×Ô±ÕÖ¢Æ×ϵÕϰ­ (Autism Spectrum Disorder, ASD£©ÑùÐÐΪ¡£

»ùÓÚÉÏÊö½á¹û£¬×÷Õß¹¹½¨Ash1lEmx1-cKOСÊó£¨ÌØÒìÐÔÔÚǰÄÔ£¬ÌرðÊÇÐÂÆ¤²ãºÍº£ÂíÇøÇóýAsh1l,ͼ1G-I£©£¬²¢Í¨¹ýÐÐΪѧ·¶Ê½·¢ÏÖ£¬Ç°ÄÔAsh1lµ¥±¶Ìå²»×ãµ¼ÖÂСÊóASDÑùÐÐΪ£¨Í¼1J-L£©¡£
AGÑÇÓ鼯ÍÅ¡¤(Öйú)¹Ù·½ÍøÕ¾
ͼ1 Ash1lµ¥±¶Ìå²»×ãµ¼ÖÂСÊóµÄASDÑù±íÐÍ
 
Ash1lÍ»±äСÊó´æÔÚ±æ±ðÄÜÁ¦È±ÏÝ

½ÓÏÂÀ´£¬Ñо¿ÈËÔ±¶ÔAsh1lȱʧСÊóµÄѧϰÐÐΪ½øÐÐÆÀ¹À£¬½èÖúÌõ¼þÐԿ־巴É䷶ʽ·¢ÏÖ£¬Ash1l+/-СÊóºÍWTСÊó¾ùѧ»áÁËÇé¾³ÐÔ¿Ö¾åÌõ¼þ·´É䣬²¢±íÏÖ³öÀàËÆµÄ¿Ö¾å¼ÇÒäÖØÌáˮƽ£¬È»¶øAsh1l+/-СÊóÔÚ¿Ö¾åѧϰµÄµÚÈýÌì±íÏÖ³öľ½©ÐÐΪ£¨freezing, ÀÏÊóµÄÒ»ÖÖ·ÀÓù·´Ó¦£©Ï½µ £»´ËÍ⣬ÔÚAsh1l+/-СÊóÖÐδ¹Û²ìµ½Á½ÖÖ²»Í¬»·¾³ÏµÄľ½©ÐÐΪ²îÒ죨WTСÊóÔÚcontext AÖбíÏÖ³ö½Ï¸ßµÄľ½©ÐÐΪ£¬ÔÚcontext B£¨Ð»·¾³£©ÖбíÏÖ³ö½ÏµÍµÄľ½©ÐÐΪ£©£¬ÌáʾÁËAsh1l+/-СÊ󱿱ðÄÜÁ¦ÊÜËð£¨Í¼2A,B£©¡£

ÔÚÒôµ÷ÒÀÀµµÄ±æ±ð·¶Ê½£¨Í¼2C-E£©ºÍ»ùÓÚÒôµ÷µÄGo-No-goÐÐΪ·¶Ê½£¨Í¼2F-H£©ÖУ¬Ash1l+/-СÊóͬÑù±íÏÖ³öÃ÷ÏÔµÄÌý¾õ±æ±ðÕϰ­£¨Ìý¾õÄԸɷ´Ó¦£¨ABR£©²âÊÔAsh1l+/-СÊóÎÞÃ÷ÏÔµÄÌýÁ¦Ëðʧ£©¡£

ΪÁËÑé֤ǰÄÔÉñ¾­ÔªÖÐAsh1lȱʧÊÇ·ñ»áµ¼ÖÂÓëAsh1l+/-СÊóÀàËÆµÄ±æ±ðÄÜÁ¦Õϰ­ÏÖÏó£¬×÷Õß½èÖúAsh1lEmx1-cKOСÊó½øÐÐÏà¹ØÐÐΪѧ·¶Ê½£¬·¢ÏÖAsh1lEmx1-cKOСÊóÓë¿Ö¾å¼ÇÒäÏà¹ØµÄÌý¾õ±æ±ðÄÜÁ¦Ã÷ÏÔÊÜËð£¨Í¼2J,K£©¡£ÕâÖÖAsh1lÍ»±äСÊóµÄ±æ±ðÄÜÁ¦Òì³£·ûºÏ²¿·ÖASD»¼ÕßµÄÁÙ´²±íÏÖ¡£Ç°ÄÔAsh1lȱʧ¿Éµ¼ÖÂÍ»´¥ºÍÉñ¾­»·Â·¹¦ÄÜÕϰ­£¬ÒÔ¼°±æ±ðÐÐΪÕϰ­¡£AGÑÇÓ鼯ÍÅ¡¤(Öйú)¹Ù·½ÍøÕ¾
AGÑÇÓ鼯ÍÅ¡¤(Öйú)¹Ù·½ÍøÕ¾Í¼2 Ash1l+/-СÊó±íÏÖ³öÕý³£µÄѧϰÄÜÁ¦£¬µ«±æ±ðÄÜÁ¦ÊÜËð
 
Ash1lÒÔϸ°û×ÔÖ÷ЧӦµÄ·½Ê½½éµ¼»î¶¯ÒÀÀµµÄÍ»´¥ÐÞ¼ô¹ý³Ì
Ëæºó£¬×÷Õß½èÖú¸ß¶û»ùȾɫ·¢ÏÖ£¬1ÔÂÁäµÄAsh1l+/-СÊ󯤲ãÉñ¾­ÔªºÍ±³²àÎÆ×´ÌåÖм¬Éñ¾­Ôª£¨MSNs£©µÄÊ÷Í»¼¬ÃܶÈÏÔÖøÔö¼Ó£¨Í¼3A£©£¬ÎªÑо¿ÕâÖÖÏÖÏóÊÇ·ñÔ´ÓÚÍ»´¥Ïû³ý¹ý³Ì£¨synapse elimination£©µÄ¼õÉÙ£¬Ñо¿ÈËÔ±Ñо¿ÁËAsh1+/-СÊóÔ­´úƤ²ãÉñ¾­ÔªµÄÍ»´¥Ãܶȱ仯¡£Óñí´ïChR2¹âÃôµ°°×µÄÂý²¡¶¾ÔØÌ壨Lenti-CaMKIIa-ChR2£©¸ÐȾÅàÑøµÄÉñ¾­Ôª£¬²¢ÓÃLED´Ì¼¤£¨Í¼3B£©£¬·¢ÏÖWTÉñ¾­ÔªÔÚLED´Ì¼¤ºó24hÊ÷ͻͻ´¥ËØ£¨SYP£©ÃܶÈÏÔÖø½µµÍ£¬¶øAsh1l+/-×éÔòδ¹Û²ìµ½ÕâÖÖÏÖÏó£¨Í¼3C,D£©£¬ÌáʾÁËAsh1l¿ÉÄܽ鵼Á˻ÒÀÀµµÄÍ»´¥ÐÞ¼ô¹ý³Ì¡ £»îÌå³ÉÏñ½á¹ûÏÔʾ£¬Ash1l+/-×éÅàÑøµÄÉñ¾­ÔªÖУ¬»îÐÔÒÀÀµµÄÍ»´¥Ïû³ý¹ý³Ì±»Ï÷Èõ¡£

´ËÍ⣬×÷Õß»¹Ñо¿ÁËÔÚСÊóÐÂÆ¤²ãÖлîÐÔÒÀÀµµÄÍ»´¥Ïû³ý£¬×·×ÙÁËÌý¾õƤ²ã£¨auditory cortex, AUD£©µ½ºó¶¥Ò¶Æ¤²ã£¨posterior parietal cortex, PTLp£©³¤¾àÀëͶÉäÖáÍ»µÄ±ä»¯¡£Ñо¿ÈËÔ±½«AAV-EF1a-DIO-EYFP×¢ÉäÔÚRbp4-CreСÊóAUD£¬ÌØÒìÐÔ±ê¼ÇÌý¾õƤ²ãL5Éñ¾­Ôª£¨Í¼3H£©¡£Ð¡Êó½ÓÊÜÒôµ÷ÒÀÀµµÄ¿Ö¾åÌõ¼þѵÁ·£¬³ÉÏñ¹Û²ìÖáÍ»±ä»¯·¢ÏÖ£¬Éùµ÷ÒÀÀµµÄ¿Ö¾åÌõ¼þѧϰ24hºó£¬Ash1l+/-::Rbp4-CreСÊó¡°bouton¡±£¨Í»´¥Ð¡½á£©µÄÇå³ýÃ÷ÏÔµÍÓÚWTСÊ󣬶ø¡°bouton¡±ÐγÉÔò±£³Ö²»±ä£¨Í¼3H-J£©¡£

Ϊ̽¾¿ÕâÖÖ¡°Í»´¥ÐÞ¼ô¡±¹ý³ÌµÄȱʧÊÇ·ñÓÉAsh1lȱʧÉñ¾­ÔªµÄϸ°û×ÔÖ÷ЧӦµ¼ÖµÄ£¬Ñо¿ÈËÔ±½«AAV-hSyn-CreºÍAAV-EF1a-DIO-EYFP×¢ÉäÓÚAsh1lfl/flСÊóÓÒ²àAUDÇø£¨Í¼3K£©£¬¶ÔСÊó½øÐÐÒôµ÷ÒÀÀµµÄ¿Ö¾åÌõ¼þÐÐΪѧ·¶Ê½ÑµÁ·£¬ÔÚѧϰ֮ºó½èÖúÌåÄÚ³ÉÏñ¼¼Êõ×·×ÙÍ»´¥µÄ±ä»¯£¬·¢ÏÖAsh1lȱʧµÄÉñ¾­ÔªÖÐѧϰÒÀÀµµÄÍ»´¥µÄÔö¼ÓÊýÁ¿Ã»Óз¢Éú¸Ä±ä£¬¶øÑ§Ï°ÓÕ·¢µÄÍ»´¥µÄ¼õÉÙÊýÁ¿ÏÔÖøµÍÓÚÕý³£Ð¡Êó£¨Í¼3K-M£©¡£ÕâЩÊý¾ÝÌáʾÁËAsh1lÒÔϸ°û×ÔÖ÷ЧӦµÄ·½Ê½½éµ¼Æ¤²ãÉñ¾­ÔªµÄ»î¶¯ÒÀÀµµÄÍ»´¥ÐÞ¼ô¹ý³Ì¡£
AGÑÇÓ鼯ÍÅ¡¤(Öйú)¹Ù·½ÍøÕ¾
AGÑÇÓ鼯ÍÅ¡¤(Öйú)¹Ù·½ÍøÕ¾Í¼3 Ash1lÒÔϸ°û×ÔÖ÷ЧӦµÄ·½Ê½½éµ¼»î¶¯ÒÀÀµµÄÍ»´¥ÐÞ¼ô¹ý³Ì

Ash1lµ÷¿ØÓ×ÊóºÍ³ÉÄêСÊóÖÐEphA7µÄ±í´ï
½ÓÏÂÀ´£¬×÷ÕßÑо¿ÁËÆä·Ö×Ó»úÖÆ£¬Í¨¹ý¶Ôת¼×é·ÖÎö¼°»ùÒò±¾ÌåÂÛ£¨GO£©·ÖÎö·¢ÏÖ£¬EphÊÜÌåEphA7ÔÚÌý¾õƤ²ãºÍ±³²àÎÆ×´ÌåÖеıí´ï¾ùÏÔÖøÏµ÷£¨Í¼4A-C£©£¬»ùÓÚ´Ë£¬Ñо¿ÈËÔ±½øÒ»²½½«EphA7×÷Ϊ²ÎÓëAsh1l½éµ¼µÄÍ»´¥ÐÞ¼ô¹ý³ÌµÄÖØÒª»ùÒòÖ®Ò»½øÐÐÁËÑо¿¡£
EphÊÜÌå¼°ÆäÅäÌå Ephrin ͳ³ÆÎªEph¼Ò×åµ°°×£¬Êǵ°°×ÀÒ°±Ëἤø¼Ò×åÖеÄ×î´ó³ÉÔ±¡£Eph/ephrinµ°°××÷Ϊϸ°û±íÃæ·Ö×Ó£¬²ÎÓëµ÷½ÚÍ»´¥µÄÐγɼ°Éñ¾­ÔªµÄ¿ÉËÜÐÔ£¬EphA7ÊDZàÂëEphÊÜÌåÖÐ14¸öÊÜÌåµ°°×»ùÒòÖ®Ò»£¬ÔÚÆ¤ÖÊ·¢ÓýºÍÍ»´¥¹¦ÄÜÖз¢»ÓÖØÒª×÷Óá£
Ëæºó£¬Ñо¿ÈËÔ±½èÖúÒôµ÷ÒÀÀµµÄ¿Ö¾åÌõ¼þÐÐΪѧ·¶Ê½£¬ÔÚÌåÄÚ/ÌåÍâ¾ù·¢ÏÖAsh1l+/-СÊóÌý¾õƤ²ã»î¶¯ÒÀÀµµÄÉñ¾­ÔªÖÐEphA7±í´ïÔ¶µÍÓÚWTСÊóµÄ£¨Í¼4D-I£©£¬ÌáʾÁËÔÚAsh1l+/-СÊóÖÐEphA7»î¶¯ÓÕµ¼±í´ïÊÜËð¡£
AGÑÇÓ鼯ÍÅ¡¤(Öйú)¹Ù·½ÍøÕ¾
ͼ4 Ash1lµ÷¿ØÓ×ÊóºÍ³ÉÄêСÊóÖÐEphA7µÄ±í´ï

Ash1lͨ¹ýÞ׿¹EZH2-H3K27me3À´µ÷¿ØEphA7µÄ±í´ï
½øÒ»²½£¬×÷Õß̽¾¿Ash1lÊÇÈçºÎ²ÎÓëµ÷¿ØEphA7»î¶¯ÓÕµ¼±í´ï£¬Í¨¹ýȾɫÖÊÃâÒß³Áµí¼¼Êõ£¨ChIP£©·¢ÏÖ£¬Ash1lµÄÖ±½Ó°ÐµãH3K36me2ÔÚWTºÍAsh1l+/-СÊóAUD EphA7»ùÒòλµã¸½½üûÓÐÃ÷ÏÔ²îÒ죬Ȼ¶øH3K27me3Ðźţ¨×éµ°°×¼×»ù×ªÒÆÃ¸¸´ºÏÌåPRC2´ß»¯µÄÒÖÖÆÐÔ±ê¼ÇÎÔÚAsh1l+/-СÊóEphA7»ùÒòλµãÏÔÖøÔö¼Ó£¨Í¼5A,B£©¡£Í¬Ê±£¬Ash1l+/-СÊóÖÐH3K27ac£¨Ò»¸ö»îÔ¾µÄÔöÇ¿±ê¼Ç¡£H3K27acÓëH3K27me3¹²ÏíÒ»¸öλÖ㬴æÔÚÞ׿¹×÷Óᣣ©±í´ï³ÖÐøÏ½µ£¬ÓÃNaB£¨×éµ°°×È¥ÒÒõ £»¯Ã¸ÒÖÖÆ¼Á£©Ô¤´¦ÀíÅàÑøµÄÉñ¾­Ôª·¢ÏÖ£¬´Ì¼¤Ash1l+/-Éñ¾­ÔªºóH3K27acÉý¸ß£¬EphA7±í´ï»Ö¸´£¨Í¼5C,D£©¡£Í¬ÑùµØ£¬ÐÐΪѧ½á¹ûÏÔʾ£¬Ash1l+/-СÊóÖÐH3K27me3¡¢EZH2£¨PRC2¸´ºÏÌåµÄÒ»¸öÖØÒªµÄ´ß»¯Ã¸£©±í´ïˮƽÏÔÖøÔö¼Ó£¨Í¼5E-G£©¡£Í¨¹ýUNC1999£¨EZH1/2ÒÖÖÆ¼Á£©¶ÔÅàÑøµÄÉñ¾­Ôª½øÐÐÔ¤´¦Àí£¬·¢ÏÖAsh1l+/-¼¤»îµÄÉñ¾­ÔªÖÐEphA7±í´ïÊܵ½ÒÖÖÆµÄÏÖÏóµÃµ½¸ÄÉÆ£¨Í¼5I£©¡£ÉÏÊö½á¹ûÌáʾÁË£¬Ash1lÔÚ»îÐÔÒÀÀµµÄPRC2½éµ¼µÄת¼ÒÖÖÆÀÛ»ýÖз¢»ÓÞ׿¹×÷Ó㬴ӶøÔÊÐíEphA7ÔÚ¼¤»îµÄÉñ¾­ÔªÖбí´ï¡£
AGÑÇÓ鼯ÍÅ¡¤(Öйú)¹Ù·½ÍøÕ¾
EphA7¸ß±í´ï¿É¸ÄÉÆAsh1l+/-СÊóÍ»´¥ÐÞ¼ô¹ý³ÌȱÏݺÍÐÐΪÒì³£
»ùÓÚÉÏÊö½á¹û£¬Ñо¿ÈËÔ±Ñо¿ÁËÌá¸ßEphA7ÊÜÌå»îÐÔÊÇ·ñÄܸÄÉÆAsh1lÍ»±äСÊóµÄÍ»´¥ÐÞ¼ô¹ý³ÌȱÏݺÍÐÐΪÒì³£¡£Ephrin-A5ÊÇEphA7µÄ¸ßÇ׺ÍÁ¦ÅäÌ壬²ÎÓëÏÂÓÎÐźÅ[3,4]¡£×÷ÕßÔÚÅàÑøµÄÉñ¾­ÔªºÍСÊóÌý¾õƤ²ãÖÐÓ¦ÓÃEphrin-A5¶à¾ÛÌåµÄFcÈںϵ°°×£¨Ephrin-A5 Fc£©Ö±½Ó´Ì¼¤EphA7»îÐÔ[5,6]£¬·¢ÏÖ¸ÄÉÆÁËAsh1lÍ»±äСÊóµÄÍ»´¥ÐÞ¼ô¹ý³ÌºÍÐÐΪÒì³££¨Í¼6£©¡£
AGÑÇÓ鼯ÍÅ¡¤(Öйú)¹Ù·½ÍøÕ¾

ͼ6 Ephrin-A5¼¤»îEphA7¸ß±í´ïAsh1l+/-СÊóÍ»´¥ÐÞ¼ô¹ý³ÌȱÏݺÍÐÐΪÒì³£

½áÂÛ
±¾ÎĽèÖúת»ùÒòÄ£ÐÍÊó¡¢¶àÖÖÐÐΪѧ·¶Ê½¡¢¹âÒÅ´«Ñ§¼¼Êõ¡¢»îÌå³ÉÏñת¼×é·ÖÎö¼°»ùÒò±¾ÌåÂÛ·ÖÎöµÈ¶àÖÖ¼¼ÊõÊֶΣ¬Ñо¿·¢ÏÖǰÄÔÉñ¾­ÔªAsh1lµ¥±¶Ìå²»×ã¿Éµ¼ÖÂСÊó²úÉú¹µÍ¨À§ÄÑ¡¢Öظ´¿Ì°åÐÐΪ¡¢Éç½»Õϰ­µÈÀàËÆ×Ô±ÕÖ¢Ñù±íÐÍ£¬²¢»úÖÆÉÏÆÆ»µ»î¶¯ÒÀÀµµÄÍ»´¥ÐÞ¼ô¹ý³Ì£¬ÕâÊÇÒÔϸ°û×ÔÖ÷ЧӦ·½Ê½½éµ¼µÄ¡£½øÒ»²½Ñо¿·¢ÏÖ£¬Ash1l¿Éͨ¹ý½éµ¼EZH2-H3K27me3È¥ÒÖÖÆ×÷ÓÃÌá¸ßEphA7µÄ»îÐÔÒÀÀµ±í´ï£¬½ø¶øÓ°ÏìÍ»´¥Ïû³ý¹ý³Ì£¬²¢¸ÄÉÆAsh1l+/-СÊ󱿱ðÄÜÁ¦Õϰ­¼°ÐÐΪÕϰ­¡£¸ÃÑо¿ÓÐÖúÓÚÉîÈëÁ˽âASDÏà¹Ø·¢²¡»úÖÆ£¬ÎªÆä¸ÉÔ¤ÖÎÁÆÌṩÁËеÄ˼·¡£

AGÑÇÓ鼯ÍÅ¡¤(Öйú)¹Ù·½ÍøÕ¾

×÷Õß½éÉܼ°»ù½ðÐÅÏ¢
ÕýÔÚÉϿƴó¹Ü¼ªËɽÌÊÚ¿ÎÌâ×é½øÐкÏ×÷Ñо¿µÄ2017¼¶²©Ê¿Ñо¿ÉúãÆÓîÔó(Ç廪´óѧ)ºÍÉϿƴóÉúÃüѧԺµÄÌïÃçÃ粩ʿΪ±¾ÎĵĹ²Í¬µÚÒ»×÷Õß¡£ÉϿƴóÉúÃüѧԺÑо¿Éú 2016¼¶³Âç÷骡¢2017¼¶¹ùÐÞÏÍ¡¢2018¼¶ÀîÃÈ¡¢2019¼¶ÖÜî¸Ò²¶Ô±¾Ñо¿×ö³öÁËÖØÒª¹±Ïס£¹Ü¼ªËɽÌÊÚ¡¢Çൺ´óѧ¸½ÊôÒ½ÔºÁõÊÀ¹ú½ÌÊÚºÍÇ廪´óѧÐÜΡ½ÌÊÚΪ±¾ÎĵĹ²Í¬Í¨Ñ¶×÷Õߣ¬Ñо¿µÃµ½Öйú¿ÆÑ§ÔºÒÅ´«·¢ÓýËùÎâÇà·åÑо¿×é¡¢ÉϺ£Àí¹¤´óѧлºìÑо¿×éµÄ´óÁ¦Ö§³Ö¡£Ñо¿Ò²µÃµ½ÁËÉϿƴóÆÝ쿽ÌÊÚ¡¢·¶¸ß·å½ÌÊÚºÍÉϺ£½»Í¨´óѧҽѧԺÐì骽ܽÌÊÚ´óÁ¿µÄÓÐÒæ°ïÖú¡£
¸ÃÑо¿Êܵ½¿Æ¼¼´´ÐÂ2030-ÖØ´óÏîÄ¿×ÊÖú£¬ºÍ×ÔÈ»¿ÆÑ§»ù½ðÏîÄ¿ÒÔ¼°ÉϺ£ÊпÆÎ¯ÏîĿ֧³Ö¡£

AGÑÇÓ鼯ÍŹٷ½ÍøÕ¾ÉúÎïÓÐÐÒÌṩʵÑéÖÐʹÓõÄAAV¡¢Âý²¡¶¾ÔØÌ壬ÓÃʵ¼ÊÐж¯ÖúÁ¦ÖйúÄÔ¿ÆÑ§µÄ·¢Õ¹¡£

²Î¿¼ÎÄÏ×
[1] Liu, S.G., Tian, M.M., He, F., Li, J.N., Xie, H., Liu, W.M., Zhang, Y.T., Zhang, R., Yi, M.J.,Che, F.Y., et al. (2020). Mutations in ASH1L confer susceptibility to Tourette syndrome. Mol Psychiatr 25, 476-490.
[2] Zhu, T., Liang, C., Li, D., Tian, M., Liu, S., Gao, G., and Guan, J.S. (2016). Histone methyltransferase Ash1L mediates activity-dependent repression of neurexin-1alpha. Sci Rep 6, 26597.
[3] Beuter, S., Ardi, Z., Horovitz, O., Wuchter, J., Keller, S., Saha, R., Tripathi, K., Anunu, R., Kehat, O., Kriebel, M., et al. (2016).  Sci Rep 6,1451 29710.
[4] Nguyen, T.M., Arthur, A., Zannettino, A.C.W., and Gronthos, S. (2017). EphA5 and EphA7 forward signaling enhances human hematopoietic stem and progenitor cell maintenance,migration, and adhesion via Rac 1 activation. Exp Hematol 48, 72-78.
[5] Clifford, M.A., Athar, W., Leonard, C.E., Russo, A., Sampognaro, P.J., Van der Goes, M.S., Burton, D.A., Zhao, X.M., Lalchandani, R.R., Sahin, M., et al. (2014b). EphA7 signaling guides cortical dendritic development and spine maturation. P Natl Acad Sci USA 111, 4994-4999.
[6] Depaepe, V., Suarez-Gonzalez, N., Dufour, A., Passante, L., Gorski, J.A., Jones, K.R., Ledent, C., and Vanderhaeghen, P. (2005). Ephrin signalling controls brain size by regulating apoptosis of neural progenitors. Nature 435, 1244-1250.

Copyright ? ÉϺ£AGÑÇÓ鼯ÍŹٷ½ÍøÕ¾ÉúÎï¼¼Êõ£¨¼¯ÍÅ£©¹É·ÝÓÐÏÞ¹«Ë¾    µØÖ·£ºÉϺ£ÊÐÆÖ¶«ÐÂÇø¹ú¼ÊÒ½Ñ§Ô°Çø×ÏÆ¼Â·908Ū19ºÅÂ¥

AGÑÇÓ鼯ÍÅ¡¤(Öйú)¹Ù·½ÍøÕ¾

µã»÷ѯ¼Û

¡¾ÍøÕ¾µØÍ¼¡¿